MCID: NRG005
MIFTS: 27

Neurogenic Hypertension malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Hypertension

Aliases & Descriptions for Neurogenic Hypertension:

Name: Neurogenic Hypertension 50 69

Classifications:



Summaries for Neurogenic Hypertension

MalaCards based summary : Neurogenic Hypertension is related to neuronitis and neutropenia monocytopenia deafness. An important gene associated with Neurogenic Hypertension is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Anti-Bacterial Agents and Antibiotics, Antitubercular have been mentioned in the context of this disorder. Affiliated tissues include brain, medulla oblongata and kidney.

Related Diseases for Neurogenic Hypertension

Diseases related to Neurogenic Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 neuronitis 9.8
2 neutropenia monocytopenia deafness 9.8 ACE2 ENPEP
3 cervicitis 9.8
4 obesity 9.7
5 cerebritis 9.7
6 atherosclerosis 9.5
7 sleep apnea 9.5
8 obstructive sleep apnea 9.5
9 renal hypertension 9.5
10 cerebral atherosclerosis 9.5
11 porphyria 9.5
12 thyroiditis 9.5
13 hypoxia 9.5
14 syncope 9.5

Graphical network of the top 20 diseases related to Neurogenic Hypertension:



Diseases related to Neurogenic Hypertension

Symptoms & Phenotypes for Neurogenic Hypertension

Drugs & Therapeutics for Neurogenic Hypertension

Drugs for Neurogenic Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
2 Antibiotics, Antitubercular Phase 3
3 Anti-Infective Agents Phase 3,Phase 1,Phase 2
4 Omega 3 Fatty Acid Nutraceutical Phase 3
5 carnitine Nutraceutical Phase 3
6
Minocycline Approved, Investigational Phase 1, Phase 2 10118-90-8 5281021
7
Fesoterodine Approved Phase 2 286930-02-7, 286930-03-8 6918558
8 Cholinergic Agents Phase 2
9 Cholinergic Antagonists Phase 2
10 Muscarinic Antagonists Phase 2
11 Neurotransmitter Agents Phase 2,Early Phase 1
12
Yohimbine Approved, Vet_approved Early Phase 1 146-48-5 8969
13
Melatonin Approved, Nutraceutical, Vet_approved Early Phase 1 73-31-4 896
14 Adrenergic Agents Early Phase 1
15 Adrenergic alpha-Antagonists Early Phase 1
16 Adrenergic Antagonists Early Phase 1
17 Antihypertensive Agents Early Phase 1
18 Antioxidants Early Phase 1
19 Autonomic Agents Early Phase 1
20 Central Nervous System Depressants Early Phase 1
21 Mydriatics Early Phase 1
22 Peripheral Nervous System Agents Early Phase 1
23 Protective Agents Early Phase 1
24 Yohimbe Nutraceutical Early Phase 1

Interventional clinical trials:


id Name Status NCT ID Phase
1 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3
2 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3
3 Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients Recruiting NCT02133885 Phase 1, Phase 2
4 Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) Recruiting NCT02676154 Phase 2
5 Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients Recruiting NCT02133872 Phase 1
6 Study 3: Minocycline Decreases Microglia Activation Not yet recruiting NCT02213575 Phase 1
7 Adolescent Blood Pressure Variation and Ventricular Mass Completed NCT00005200
8 Brain fMRT In Takotsubo Cardiomyopathy Recruiting NCT02240056
9 Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension Not yet recruiting NCT02963181 Early Phase 1

Search NIH Clinical Center for Neurogenic Hypertension

Genetic Tests for Neurogenic Hypertension

Anatomical Context for Neurogenic Hypertension

MalaCards organs/tissues related to Neurogenic Hypertension:

39
Brain, Medulla Oblongata, Kidney, Heart, Hypothalamus, Thyroid, Pons

Publications for Neurogenic Hypertension

Articles related to Neurogenic Hypertension:

(show top 50) (show all 138)
id Title Authors Year
1
Putative Mechanism of Salt-Dependent Neurogenic Hypertension: Cell-Autonomous Activation of Organum Vasculosum Laminae Terminalis Neurons by Hypernatremia. ( 27895191 )
2017
2
Contribution of Orexin to the Neurogenic Hypertension in BPH/2J Mice. ( 26975709 )
2016
3
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. ( 27754127 )
2016
4
Furosemide modifies heart hypertrophy and glycosaminoglycan myocardium content in a rat model of neurogenic hypertension. ( 27221775 )
2016
5
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. ( 27643054 )
2016
6
Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension. ( 27754863 )
2016
7
Carotid body over activity induces respiratory neurone channelopathy contributing to neurogenic hypertension. ( 25900825 )
2015
8
Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. ( 25489058 )
2015
9
I+-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. ( 26254330 )
2015
10
In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. ( 26834545 )
2015
11
Presympathetic neuron dysfunction--time to reconsider increased intrinsic activity as the cause of neurogenic hypertension. ( 24987020 )
2014
12
Different impacts of I+- and I^-blockers in neurogenic hypertension produced by brainstem lesions in rat. ( 24614323 )
2014
13
Specific respiratory neuron types have increased excitability that drive presympathetic neurones in neurogenic hypertension. ( 24688126 )
2014
14
Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice. ( 24275840 )
2013
15
Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. ( 22746319 )
2013
16
Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model. ( 23747290 )
2013
17
The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. ( 24002774 )
2013
18
Stabilization of hypoxia inducible factor-1I+ ameliorates acute renal neurogenic hypertension. ( 24309492 )
2013
19
Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. ( 24014829 )
2013
20
Chiari I malformation with neurogenic hypertension: case report. ( 22890471 )
2012
21
Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link? ( 22562144 )
2012
22
Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. ( 22958438 )
2012
23
Neurogenic hypertension: revelations from genome-wide gene expression profiling. ( 22639016 )
2012
24
Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. ( 21755262 )
2011
25
Coupling between respiratory and sympathetic activities as a novel mechanism underpinning neurogenic hypertension. ( 21445721 )
2011
26
Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension. ( 21487032 )
2011
27
Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. ( 21536990 )
2011
28
Contributions of vascular inflammation in the brainstem for neurogenic hypertension. ( 21601658 )
2011
29
Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. ( 19923158 )
2010
30
Brain microglial cytokines in neurogenic hypertension. ( 20547972 )
2010
31
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. ( 19926873 )
2010
32
Neurogenic hypertension. ( 20407134 )
2010
33
Inflammation and neurogenic hypertension: a new role for the circumventricular organs? ( 20651292 )
2010
34
Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The kidney is not always the target in neurogenic hypertension. ( 21188820 )
2010
35
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. ( 19762685 )
2009
36
Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species: new targets for neurogenic hypertension? ( 19114641 )
2009
37
Do changes in the coupling between respiratory and sympathetic activities contribute to neurogenic hypertension? ( 19413588 )
2009
38
Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. ( 19047792 )
2009
39
Is neurogenic hypertension related to vascular inflammation of the brainstem? ( 18585782 )
2009
40
Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. ( 19114648 )
2009
41
Specific inflammatory condition in nucleus tractus solitarii of the SHR: novel insight for neurogenic hypertension? ( 18722165 )
2008
42
Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. ( 18443753 )
2008
43
Aminopeptidase A: could it be a novel target for neurogenic hypertension? ( 18362227 )
2008
44
Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. ( 17122386 )
2007
45
Neurovascular compression of the medulla: can it cause neurogenic hypertension? ( 17215662 )
2007
46
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. ( 17519130 )
2007
47
Compression of the rostral ventrolateral medulla by a vagal schwannoma of the cerebellomedullary cistern presenting with refractory neurogenic hypertension: case report. ( 16723872 )
2006
48
Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. ( 16716903 )
2006
49
Role of calcitonin gene-related peptide in the phenol-induced neurogenic hypertension in rats. ( 15120475 )
2004
50
Neurogenic hypertension: is the enigma of its origin near the solution? ( 14676221 )
2004

Variations for Neurogenic Hypertension

Expression for Neurogenic Hypertension

Search GEO for disease gene expression data for Neurogenic Hypertension.

Pathways for Neurogenic Hypertension

GO Terms for Neurogenic Hypertension

Biological processes related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.26 ACE2 ENPEP
2 angiotensin maturation GO:0002003 9.16 ACE2 ENPEP
3 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE2 ENPEP
4 angiotensin catabolic process in blood GO:0002005 8.62 ACE2 ENPEP

Molecular functions related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.16 ACE2 ENPEP
2 peptidase activity GO:0008233 8.96 ACE2 ENPEP
3 metallopeptidase activity GO:0008237 8.62 ACE2 ENPEP

Sources for Neurogenic Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....